JP2018523673A5 - - Google Patents

Download PDF

Info

Publication number
JP2018523673A5
JP2018523673A5 JP2018507602A JP2018507602A JP2018523673A5 JP 2018523673 A5 JP2018523673 A5 JP 2018523673A5 JP 2018507602 A JP2018507602 A JP 2018507602A JP 2018507602 A JP2018507602 A JP 2018507602A JP 2018523673 A5 JP2018523673 A5 JP 2018523673A5
Authority
JP
Japan
Prior art keywords
hcab
pdgf
seq
amino acid
specificity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2018507602A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018523673A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/046595 external-priority patent/WO2017030909A1/en
Publication of JP2018523673A publication Critical patent/JP2018523673A/ja
Publication of JP2018523673A5 publication Critical patent/JP2018523673A5/ja
Pending legal-status Critical Current

Links

JP2018507602A 2015-08-14 2016-08-11 Ｐｄｇｆに対する重鎖のみ抗体 Pending JP2018523673A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562205191P 2015-08-14 2015-08-14
US62/205,191 2015-08-14
US201662333772P 2016-05-09 2016-05-09
US62/333,772 2016-05-09
PCT/US2016/046595 WO2017030909A1 (en) 2015-08-14 2016-08-11 Heavy chain only antibodies to pdgf

Publications (2)

Publication Number Publication Date
JP2018523673A JP2018523673A (ja) 2018-08-23
JP2018523673A5 true JP2018523673A5 (OSRAM) 2019-08-22

Family

ID=56740535

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018507602A Pending JP2018523673A (ja) 2015-08-14 2016-08-11 Ｐｄｇｆに対する重鎖のみ抗体

Country Status (7)

Country Link
US (5) US10308711B2 (OSRAM)
EP (1) EP3334762A1 (OSRAM)
JP (1) JP2018523673A (OSRAM)
AU (1) AU2016307943A1 (OSRAM)
CA (1) CA2992788A1 (OSRAM)
HK (1) HK1254093A1 (OSRAM)
WO (1) WO2017030909A1 (OSRAM)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10206813B2 (en) 2009-05-18 2019-02-19 Dose Medical Corporation Implants with controlled drug delivery features and methods of using same
US12478503B2 (en) 2009-05-18 2025-11-25 Glaukos Corporation Implants with controlled drug delivery features and methods of using same
EP3792279A3 (en) 2015-07-29 2021-07-07 Allergan, Inc. Heavy chain only antibodies to ang-2

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
USRE30985E (en) 1978-01-01 1982-06-29 Serum-free cell culture media
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
EP0206448B1 (en) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
GB8516415D0 (en) 1985-06-28 1985-07-31 Celltech Ltd Culture of animal cells
US4927762A (en) 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US5204244A (en) 1987-10-27 1993-04-20 Oncogen Production of chimeric antibodies by homologous recombination
EP0435911B1 (en) 1988-09-23 1996-03-13 Cetus Oncology Corporation Cell culture medium for enhanced cell growth, culture longevity and product expression
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
US6797492B2 (en) 1991-05-17 2004-09-28 Merck & Co., Inc. Method for reducing the immunogenicity of antibody variable domains
US5534615A (en) 1994-04-25 1996-07-09 Genentech, Inc. Cardiac hypertrophy factor and uses therefor
US5869079A (en) 1995-06-02 1999-02-09 Oculex Pharmaceuticals, Inc. Formulation for controlled release of drugs by combining hydrophilic and hydrophobic agents
ES2273415T3 (es) 1997-04-07 2007-05-01 Genentech, Inc. Anticuerpos anti-vegf.
US6884879B1 (en) 1997-04-07 2005-04-26 Genentech, Inc. Anti-VEGF antibodies
US7117096B2 (en) 2001-04-17 2006-10-03 Abmaxis, Inc. Structure-based selection and affinity maturation of antibody library
GB0110029D0 (en) 2001-04-24 2001-06-13 Grosveld Frank Transgenic animal
US20100081792A1 (en) * 2001-06-28 2010-04-01 Smithkline Beecham Corporation Ligand
CN1301692C (zh) 2002-09-18 2007-02-28 阿勒根公司 眼植入物导入的器械
GB0230203D0 (en) * 2002-12-27 2003-02-05 Domantis Ltd Fc fusion
US7758859B2 (en) 2003-08-01 2010-07-20 Genentech, Inc. Anti-VEGF antibodies
US20050282233A1 (en) 2004-03-05 2005-12-22 Ludwig Institute For Cancer Research Multivalent antibody materials and methods for VEGF/PDGF family of growth factors
LT2311874T (lt) 2004-07-22 2017-11-27 Erasmus University Medical Center Rotterdam Rišančiosios molekulės
US8466263B2 (en) * 2005-12-02 2013-06-18 Dana-Farber Cancer Institute, Inc. Carbonic anhydrase IX (G250) anitbodies
US20090307787A1 (en) 2006-01-25 2009-12-10 Franklin Gerardus Grosveld Generation of heavy-chain only antibodies in transgenic animals
MX380352B (es) * 2006-06-12 2025-03-12 Aptevo Res & Development Llc Proteinas de union multivalentes monocatenarias con funcion efectora.
TWI580694B (zh) 2007-11-30 2017-05-01 建南德克公司 抗-ｖｅｇｆ抗體
SI2274008T1 (sl) 2008-03-27 2014-08-29 Zymogenetics, Inc. Sestavki in metode za zaviranje PDGFRBETA in VEGF-A
US8133979B2 (en) 2008-12-16 2012-03-13 Hoffmann-La Roche Inc. Antibodies against human angiopoietin 2
GB0905023D0 (en) 2009-03-24 2009-05-06 Univ Erasmus Medical Ct Binding molecules
TWI426920B (zh) 2010-03-26 2014-02-21 Hoffmann La Roche 雙專一性、雙價抗－ｖｅｇｆ／抗－ａｎｇ－２抗體
WO2012009705A1 (en) 2010-07-15 2012-01-19 Zyngenia, Inc. Ang-2 binding complexes and uses thereof
ME02637B (me) * 2010-08-20 2017-06-20 Novartis Ag Antitela za receptor 3 faktora rasta epiderma (her3)
US9527925B2 (en) 2011-04-01 2016-12-27 Boehringer Ingelheim International Gmbh Bispecific binding molecules binding to VEGF and ANG2
PH12014500483A1 (en) * 2011-09-30 2014-04-14 Regeneron Pharma Anti-erbb3 antibodies and uses thereof
US9428577B2 (en) * 2012-11-09 2016-08-30 Pfizer Inc. Platelet-derived growth factor B specific antibodies and compositions and uses thereof
BR112015010722A2 (pt) * 2012-11-09 2017-08-22 Pfizer Anticorpos específicos de fator de crescimento derivado de plaquetas de isoforma b e composições e usos dos mesmos
US10993420B2 (en) 2013-03-15 2021-05-04 Erasmus University Medical Center Production of heavy chain only antibodies in transgenic mammals
EP3792279A3 (en) * 2015-07-29 2021-07-07 Allergan, Inc. Heavy chain only antibodies to ang-2

Similar Documents

Publication Publication Date Title
JP2016504416A5 (OSRAM)
JP2018527327A5 (OSRAM)
RU2014113046A (ru) Профилактика и лечение патологических состояний глаз, вызванных комплементом
JP2020114218A5 (OSRAM)
JP2019515027A5 (OSRAM)
AU2011201340B2 (en) Novel anti-PIGF antibody
WO2008154251A4 (en) C3b antibodies and methods for the prevention and treatment of complement- associated disorders
AU2013288641B2 (en) Bispecific anti-VEGF/anti-ANG-2 antibodies and their use in the treatment of ocular vascular diseases
RU2015121755A (ru) Антагонисты ил-6 и их применение
JP2011504872A5 (OSRAM)
JP2013528607A5 (OSRAM)
JP2020515545A5 (OSRAM)
JP2017535285A5 (OSRAM)
JP2014532072A5 (OSRAM)
JP2017536414A5 (OSRAM)
JP2017534646A5 (OSRAM)
RU2014129316A (ru) Способы ингибирования глазного ангиогенеза
NZ574308A (en) Scfv antibodies which pass epithelial and/or endothelial layers
RU2018103960A (ru) Антитела против ang-2, содержащие только тяжелую цепь
JP2018510617A5 (OSRAM)
JP2012165745A5 (OSRAM)
JP2017515811A5 (OSRAM)
JP2018530574A5 (OSRAM)
HRP20251312T1 (hr) Poboljšana protutijela za il-6
JP2019531259A (ja) ＶＥ−ＰＴＰ（ＨＰＴＰ−β）を標的化するヒト化モノクローナル抗体